Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
1998-10-8
|
pubmed:abstractText |
The pharmacokinetics of cefdinir were investigated in six hemodialysis patients. For the present study, two tests were carried out, one with 4 h of hemodialysis and the other without hemodialysis. Cefdinir was given orally to each patient in a dose of 100 mg, and blood was collected serially for 48 h after dosing in the test without dialysis and for 72 h in the test with dialysis. In the test without dialysis, the maximum plasma concentration (Cmax) was 2.36 +/- 0.53 micrograms/ml (mean +/- standard deviation) and the time to Cmax was 9.00 +/- 2.45 h. The terminal elimination half-life (t1/2) and area under the concentration-time curve (AUC) were 16.95 +/- 1.20 h and 69.05 +/- 14.84 micrograms.h/ml, respectively. In the test with dialysis, t1/2 during hemodialysis decreased approximately to one-sixth of that obtained in the test without dialysis, although t1/2 in the latter elimination phase did not differ from that in the nondialysis test. AUC was reduced to 43% of that in the test without dialysis. The fractional removal of cefdinir by hemodialysis was 61%. These findings indicate that clearance of cefdinir is prolonged in patients with renal failure, and cefdinir is well removed by introduction of hemodialysis, although t1/2 (during hemodialysis) and AUC were two and eight times higher than the data previously reported for healthy volunteers, respectively. The pharmacokinetic data suggest that 100 mg of oral cefdinir once a day would result in a sufficient concentration in plasma in hemodialysis patients, but this remains to be confirmed by multiple-dose studies.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/9661010-1474165,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9661010-2037710,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9661010-2365467,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9661010-2401125,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9661010-3530782,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9661010-3777912,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9661010-456077,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9661010-7073265,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9661010-708006
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0066-4804
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
42
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1718-21
|
pubmed:dateRevised |
2009-11-18
|
pubmed:meshHeading |
pubmed-meshheading:9661010-Administration, Oral,
pubmed-meshheading:9661010-Adult,
pubmed-meshheading:9661010-Cephalosporins,
pubmed-meshheading:9661010-Humans,
pubmed-meshheading:9661010-Kidney Failure, Chronic,
pubmed-meshheading:9661010-Male,
pubmed-meshheading:9661010-Middle Aged,
pubmed-meshheading:9661010-Renal Dialysis
|
pubmed:year |
1998
|
pubmed:articleTitle |
Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients.
|
pubmed:affiliation |
First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan. ahishida@hama-med.ac.jp
|
pubmed:publicationType |
Journal Article
|